Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

June 14, 2024

https://www.globenewswire.com/news-release/2024/06/14/2898885/0/en/Autolus-Therapeutics-to-Present-Three-Clinical-Data-Updates-on-obecabtagene-autoleucel-obe-cel-in-relapsed-refractory-r-r-B-Cell-acute-lymphoblastic-leukemia-ALL-patients-at-the-20.html

LONDON, June 14, 2024 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces three abstracts to be presented at the European Hematology Association (EHA) Congress, June 13-16, 2024.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.